跳至主要内容
临床试验/NCT00003165
NCT00003165Unknown2 期

A Phase II Trial of PK1 in Women With Advanced Breast Cancer

University of Glasgow12 个研究点 分布在 1 个国家目标入组 25 人开始时间: 1997年12月最近更新:
适应症
相关药物

试验速览

阶段
2 期
入组人数
25
试验地点
12

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different forms may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of doxorubicin in treating women with advanced metastatic breast cancer.

详细描述

OBJECTIVES: I. Determine the antitumor activity of doxorubicin-HPMA conjugate (PK1) in women with advanced breast cancer.

OUTLINE: This is an open label, multicenter study. Patients receive doxorubicin-HPMA conjugate (PK1) by intravenous infusion once every 3 weeks. Patients may receive a total of 6 courses of treatment in the absence of toxicity and progressive disease.

PROJECTED ACCRUAL: 14-25 patients will be accrued for this study.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (12)

Loading locations...

相似试验

Doxorubicin in Treating Women With Advanced Breast... | 临床试验